{
    "ticker": "TENX",
    "name": "Tenax Therapeutics, Inc.",
    "description": "Tenax Therapeutics, Inc. is a clinical-stage pharmaceutical company dedicated to developing innovative therapies for patients with rare and serious diseases. Founded in 2014, Tenax focuses on advancing treatments for conditions associated with pulmonary hypertension and other unmet medical needs. The company is best known for its lead product candidate, TNX-102 SL, which is a sublingual formulation of cyclobenzaprine intended to treat fibromyalgia and other chronic pain disorders. By utilizing a unique drug delivery system, Tenax aims to enhance patient compliance and improve therapeutic outcomes. In addition to its core product pipeline, Tenax is committed to research and development efforts that explore novel applications of its drug candidates for various indications. The company\u2019s mission is rooted in improving the quality of life for patients suffering from debilitating conditions through innovative and accessible therapies. With a team of experienced professionals and a robust clinical development strategy, Tenax Therapeutics aspires to make a significant impact in the biotechnology space and contribute to the advancement of healthcare.",
    "industry": [
        "Pharmaceuticals",
        "Biotechnology"
    ],
    "headquarters": "Research Triangle Park, North Carolina, USA",
    "founded": "2014",
    "website": "https://www.tenaxthera.com",
    "ceo": "Anthony DiTonno",
    "social_media": {
        "twitter": "https://twitter.com/TenaxThera",
        "linkedin": "https://www.linkedin.com/company/tenax-therapeutics/"
    },
    "investor_relations": "https://www.tenaxthera.com/investors",
    "key_executives": [
        {
            "name": "Anthony DiTonno",
            "position": "CEO"
        },
        {
            "name": "David G. S. H. Kessler",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Pharmaceutical Products",
            "products": [
                "TNX-102 SL"
            ]
        }
    ],
    "seo": {
        "meta_title": "Tenax Therapeutics, Inc. | Innovative Treatments for Rare Diseases",
        "meta_description": "Explore Tenax Therapeutics, Inc., a clinical-stage company focused on innovative therapies for rare diseases. Learn about their drug candidates and commitment to patient care.",
        "keywords": [
            "Tenax Therapeutics",
            "Pharmaceuticals",
            "Biotechnology",
            "TNX-102 SL",
            "Rare Diseases",
            "Pulmonary Hypertension"
        ]
    },
    "faq": [
        {
            "question": "What is Tenax Therapeutics known for?",
            "answer": "Tenax Therapeutics is known for developing innovative therapies for rare and serious diseases, particularly its lead product candidate TNX-102 SL."
        },
        {
            "question": "Who is the CEO of Tenax Therapeutics?",
            "answer": "Anthony DiTonno is the CEO of Tenax Therapeutics, Inc."
        },
        {
            "question": "Where is Tenax Therapeutics headquartered?",
            "answer": "Tenax Therapeutics is headquartered in Research Triangle Park, North Carolina, USA."
        },
        {
            "question": "What are Tenax's main products?",
            "answer": "Tenax's main product is TNX-102 SL, aimed at treating fibromyalgia and other chronic pain conditions."
        },
        {
            "question": "When was Tenax Therapeutics founded?",
            "answer": "Tenax Therapeutics was founded in 2014."
        }
    ],
    "competitors": [
        "SGEN",
        "AMGN",
        "VRTX",
        "REGN"
    ],
    "related_stocks": [
        "GILD",
        "BMY",
        "PFE",
        "JNJ"
    ]
}